PTC Therapeutics (PTCT) volatility comes in on Serepta approval

September 19, 2016 12:22 PM EDT

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

PTC Therapeutics (NASDAQ: PTCT) whose Translarna drug seeks to treat nonsense mutation Duchenne muscular dystrophy is recently up 23%, after the FDA granted accelerated approval to Sarepta's (SRPT) eteplirsen, the company's treatment of Duchenne muscular dystrophy. PTCT October call option implied volatility is at 95, November is at 105; compared to its 52-week range of 88 to 330.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Options, Trader Talk

Related Entities

Options, srpt

Add Your Comment